ArticleAmerican journal of cancer research2022
Atractylon inhibits the tumorigenesis of glioblastoma through SIRT3 signaling.
Article in American journal of cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Characteristic Constituents of Maocangzhu and Beicangzhu Revealed Using Electronic Nose, Electronic Tongue, HS-GC-IMS, and UPLC-Orbitrap Technologies.Molecules (Basel, Switzerland) · 2026Article
- From Cerebrovascular Injury to Brain Cancer: The Role of Blood-Brain Barrier Dysfunction.Biomedicines · 2026Review
- A Systematic Review on Functional Bioactive Compound Atractylone: Natural Source, Pharmacological Properties and Mechanisms Insights.Food science & nutrition · 2026Review
- Characterisation of Early Biosynthetic Steps of Atractylon via an Integrative Strategy.Plant biotechnology journal · 2025Article
- Epigenetic regulation of histone modifications in glioblastoma: recent advances and therapeutic insights.Biomarker research · 2025Review
- Taurochenodeoxycholic acid suppresses the progression of glioblastoma via HMGCS1/HMGCR/GPX4 signaling pathway in vitro and in vivo.Cancer cell international · 2025Article
- HAT1/HDAC2 mediated ACSL4 acetylation confers radiosensitivity by inducing ferroptosis in nasopharyngeal carcinoma.Cell death & disease · 2025Article
- Nootkatone inhibits the progression of glioblastoma by activating the ATF4-CHOP-CHAC1 pathway.Molecular medicine (Cambridge, Mass.) · 2025Article
- Compound Tinglizi Decoction-Containing Serum Is Associated with Inhibition of PANoptosis in Cardiomyocytes via SIRT3-Related Chaperone-Mediated Autophagy of AIM2.International journal of general medicine · 2025Article
- Integrated transcriptome and metabolome analysis reveal the sesquiterpenoid biosynthesis mechanism ofFrontiers in plant science · 2025Article
- Research Progress with Atractylone as an Antitumor Agent.Molecules (Basel, Switzerland) · 2024Review
- Targeting programmed cell death via active ingredients from natural plants: a promising approach to cancer therapy.Frontiers in pharmacology · 2024Review
- The role of artificial intelligence in drug screening, drug design, and clinical trials.Frontiers in pharmacology · 2024Review
- SLC25A51 promotes tumor growth through sustaining mitochondria acetylation homeostasis and proline biogenesis.Cell death and differentiation · 2023Article
- Mechanism research and treatment progress of NAD pathway related molecules in tumor immune microenvironment.Cancer cell international · 2022Review
- SIRT3 inhibitor 3-TYP exacerbates thioacetamide-induced hepatic injury in mice.Frontiers in physiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) is the most common primary malignant brain tumor. Although there are various treatments for glioblastoma including surgery, radiotherapy, systemic therapy (chemotherapy and targeted therapy) and supportive therapy, the overall prognosis remains poor and the long-term survival rate is very low. Atractylon, a bioactive compound extracted from the Chinese herb
Indexed as
Identifiers
35693089PMC9185613W4285744436What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.